DIFFERENTIAL-EFFECTS OF PHORBOL ESTER ON EPIDERMAL GROWTH-FACTOR RECEPTORS IN ESTROGEN RECEPTOR-POSITIVE AND RECEPTOR-NEGATIVE BREAST-CANCER CELL-LINES
- 15 August 1990
- journal article
- research article
- Vol. 50 (16) , 4849-4855
Abstract
A previous study from this laboratory (Koga et al., Cancer Res., 48:2734-2739, 1988) demonstrated that the growth inhibitory effect of 1,25-dihydroxyvitamin D3 in human breast cancer cells in vitro was associated with a decline in the concentration of epidermal growth factor receptor (EGF-R). In the present study experiments were undertaken with the phorbol ester, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), an agent known to decrease EGF-R binding, in order to further define the relationship between changes in EGF-R binding and changes in growth rates in 10 human breast cancer cell lines. Treatment with TPA decreased the rate of cell proliferation in all cell lines except BT 474 in which a slight increase in proliferation rate was observed. Sensitivity to TPA was unrelated to estrogen receptor (ER) status and a wide spectrum of sensitivities was apparent. The concentrations of TPA that produced a 25% decrease in cell number ranged from < 0.25 nM for MCF 7M and BT 20 cells to > 10 nM for the HBL 100, T 47D, and ZR 75-1 cell lines. Growth inhibition was associated with a block in cell cycle progression in the G1 and G2 + M phases of the cell cycle. In all cell lines studies, except BT 474, TPA treatment resulted in a reduction in the ability of cells to bind EGF. Saturation analysis revealed marked differences between the effects of TPA on EGF binding in ER+ and ER- cell lines. In ER+ cell lines, 2-h treatment with 10 nM TPA resulted in a marked reduction in the number of high affinity EGF-R sites adn a significant decrease in binding affinity. Among this group of cell lines there was a significant positive correlation between the ability of TPA to decrease cell growth and the TPA-induced decrease in the number of EGF-R sites/cell (r = 0.82, P < 0.03). In ER- cell lines, TPA-induced growth inhibition and the minor changes in EGF-R concentration were unrelated. However, growth inhibition was negatively correlated with TPA-induced changes in apparent affinity of the EFG-R (r = 1.00, P < 0.003) and in the same rank order as the EGF-R concentration in control cells.This publication has 33 references indexed in Scilit:
- DIFFERENTIAL SENSITIVITY OF HUMAN-BREAST CANCER CELL-LINES TO THE GROWTH-INHIBITORY EFFECTS OF TAMOXIFEN1985
- PRESENCE OF TRANSFORMING GROWTH-FACTORS IN HUMAN-BREAST CANCER-CELLS1984
- Effect of 12‐O‐tetradecanoylphorbol‐13‐acetate (TPA) on the growth inhibitory and increased phosphatidylinositol (PI) responses induced by epidermal growth factor (EGF) in A431 cellsJournal of Cellular Physiology, 1983
- Tumor promoter 12-O-tetradecanoylphorbol 13-acetate, like epidermal growth factor, stimulates cell proliferation and inhibits differentiation of mouse mammary epithelial cells in culture.Proceedings of the National Academy of Sciences, 1983
- INHIBITION OF HUMAN CANCER CELL-GROWTH BY 1,25-DIHYDROXYVITAMIN-D3 METABOLITES1983
- Antagonism between Epidermal Growth Factor and Phorbol Ester Tumor Promoters in Human Breast Cancer CellsJournal of Clinical Investigation, 1981
- Mechanism of tumor promoter inhibition of cellular binding of epidermal growth factorProceedings of the National Academy of Sciences, 1979
- Binding of epidermal growth factor to primary and permanent cultures of mouse epidermal cells: Inhibition by tumor-promoting phorbol estersCancer Letters, 1979
- Biologically active phorbol esters specifically alter affinity of epidermal growth factor membrane receptorsNature, 1979
- STIMULATED DNA-SYNTHESIS IN MOUSE EPIDERMAL-CELL CULTURES TREATED WITH 12-O-TETRADECANOYL-PHORBOL-13-ACETATE1976